PT-141
Sexual function (melanocortin)
Status & caution. FDA-approved (Vyleesi) for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Use in men or other contexts is off-label / grey-market. Approved for a narrow indication; can transiently raise blood pressure and cause nausea/flushing.
At a glance
Indications & what it's studied for
Approved for low sexual desire in premenopausal women; acts centrally on melanocortin receptors. Off-label community use targets libido/erectile response in men.
Contraindications & cautions
Uncontrolled hypertension or known cardiovascular disease (it can raise BP); pregnancy.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Approved use is an on-demand subcutaneous dose ahead of anticipated activity, with a daily/monthly maximum.
Routes of administration
Subcutaneous injection; intranasal forms exist in grey markets.
Don't combine with
Avoid stacking with Melanotan I or II (overlapping melanocortin effects); caution with antihypertensives and other BP-active drugs.
Reported to stack with
No validated stacking; combining melanocortin agonists increases side-effect risk.
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Phase 3 trials (RECONNECT) support the approved indication; cardiovascular/BP effects are well documented.
Before acting on anything here, see Safety & the grey market and how to read a COA.